TrueWealth LLC’s United Therapeutics UTHR Stock Holding History

TrueWealth LLC’s Portfolio UTHR Stock Details UTHR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q1	–	Sell	-47	Closed	-$7K	–	918
2017 Q4	$7K	Buy	+47	New	+$5.97K	﹤0.01%	588

Other funds holding UTHR

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

JIM

Jupiter Investment Management London, United Kingdom $6.26B AUM 13.19% 1-Year Est. Return

TrueWealth LLC's UTHR Position: Q1 2018 in Review

TrueWealth LLC sold out of United Therapeutics (UTHR) in Q1 2018, closing a stake of 47 shares — an estimated $7K sold.

TrueWealth LLC first reported a position in UTHR in Q4 2017 and held it in 1 quarter. The position peaked at $7K in Q4 2017. 374 funds tracked by Wall St. Rank hold UTHR as of Q1 2018.

TrueWealth LLC reported no remaining United Therapeutics position as of Q1 2018 after selling out during the quarter.
TrueWealth LLC sold 47 United Therapeutics shares in Q1 2018, an estimated $7K.
TrueWealth LLC first reported a position in United Therapeutics in Q4 2017 and held it in 1 quarter.
TrueWealth LLC's United Therapeutics position peaked at $7K in Q4 2017.
374 funds tracked by Wall St. Rank held United Therapeutics as of Q1 2018.

Based on TrueWealth LLC's 13F filing for Q1 2018, filed 30 Apr 2018.